COMMUNIQUÉS West-GlobeNewswire

Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
07/05/2024
IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare [...]
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
07/05/2024
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4- [...]
Arbutus to Participate in Two Upcoming Investor Conferences
07/05/2024
WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for [...]
Altimmune to Participate at Two Upcoming Investor Conferences
07/05/2024
GAITHERSBURG, Md., May 07, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be [...]
Enable Injections Expands Strategic Partnership with Roche
07/05/2024
CINCINNATI, May 07, 2024 (GLOBE NEWSWIRE) -- Enable Injections, Inc.  ("Enable"), a leading innovator in developing and manufacturing the enFuse ® platform of wearable drug delivery device technology, today announced [...]
ITM Appoints Dr. Danielle Meyrick as Chief Medical Officer
07/05/2024
Leveraging profound knowledge in radiopharmaceutical drug development and commercial planning, Dr. Meyrick will lead the medical team in further developing and delivering on ITM's pipeline strategy After a career [...]
Coloplast Finance B.V. - Interim Financial Report, H1 2023/24
07/05/2024
H1 2023/24 Interim financial results, H1 2023/24 1 October 2023 - 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin 1) of 27%. Reported revenue in DKK grew 9% with 4%-points [...]
EyeDNA Therapeutics Announces Positive 24-month Data Presented at ARVO from Ongoing Phase I/II Trial of HORA-PDE6b Gene Therapy in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
07/05/2024
Clinically meaningful benefit in visual functions and good safety profile of HORA-PDE6b is confirmed at 24-month follow-up Phase I/II results will be discussed with US and European health authorities to define optimal [...]
CMR Surgical appoints Shlomi Cohen as Chief Financial Officer
07/05/2024
CMR Surgical appoints Shlomi Cohen as Chief Financial Officer Shlomi Cohen is a medical devices expert with significant financial and operational experience. CAMBRIDGE, UK – 7 May 2024, 07:00 (BST). CMR Surgical (CMR or [...]
Memo Therapeutics increases Series C financing to CHF 45 million
07/05/2024
PRESS RELEASE Memo Therapeutics increases Series C financing to CHF 45 million Additional CHF 20 million raised from new investors Ysios Capital and Kurma Partners as well as from existing investors Proceeds will be [...]
Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025
07/05/2024
ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS 7 May 2024 at 08.30 EEST Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025 Olli Huotari , Senior Vice [...]
Coloplast strengthens ostomy care portfolio with three significant product launches
07/05/2024
The company has received reimbursement approval in the UK for Heylo™, the world’s first digital leakage notification system, and expands its SenSura® Mio ostomy range with two new products. As part of our 2025 strategy [...]
Coloplast A/S - Announcement no. 02/2024 - Interim Financial Report, H1 2023/24
07/05/2024
H1 2023/24 Interim financial results, H1 2023/24 1 October 2023 - 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin 1) of 27%. Reported revenue in DKK grew 9% with 4%-points [...]
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
07/05/2024
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates Q1 financial highlights Total revenues of €32.8 million, including sales of €32.1 million, on track to meet anticipated full year [...]
Valneva publie ses résultats financiers du premier trimestre 2024 et fait un point sur ses activités
07/05/2024
Valneva publie ses résultats financiers du premier trimestre 2024 et fait un point sur ses activités Principaux éléments financiers du premier trimestre Chiffre d’affaires total de 32,8 millions d’euros dont 32,1 [...]
argenx to Present at BofA Securities 2024 Health Care Conference
07/05/2024
May 7, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that [...]
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update
07/05/2024
Ultimovacs remains committed to continuing the clinical development strategy and exploring multiple pathways for UV1. The negative INITIUM results have had important consequences for the Company. Implemented cash [...]
Sandoz reports first quarter 2024 sales
07/05/2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in USD) Biosimilar [...]
BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million
07/05/2024
Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosis GSK to participate in Series C Extension with equity investment Series C financing round [...]

Pages